Drug-coated balloons

Original Contribution

Outcomes Following Coronary Chronic Total Occlusion Revascularization With Drug-Coated Balloons

02/21/2024

Mehdi Madanchi, MD^1,2; Matthias Bossard, MD^1,2; Irena Majcen, PhD^1,2; Giacomo M. Cioffi, MD^1,3; Francesco Ferraro, MD⁴; Eleonora Gnan, MD^1,5; Varis Gjergjizi, MD¹; Yuan Zhi, MD¹; Vanessa Bade, BSc^1,6; Mathias Wolfrum, MD¹; Federico Moccetti, MD¹; Stefan Toggweiler, MD¹; Adrian Attinger-Toller, MD¹; Florim Cuculi, MD^1,2

Mehdi Madanchi, MD1,2; Matthias Bossa...

The study aimed to describe the safety and long-term outcomes of patients with coronary chronic total occlusions undergoing percutaneous coronary interventions with the latest generation of drug-coated balloons vs novel drug-eluting stents.

The study aimed to describe the...

02/21/2024

Journal of Invasive Cardiology

AMP 2023

Current Clinical Data on RANGER DCB: RANGER II SFA, COMPARE, and Real-World Experience with ELEGANCE

11/13/2023

Pradeep Nair, MD

Cardiovascular Institute of the South, Houma, Louisiana

Pradeep Nair, MD Cardiovascular Inst...

In this video recorded at AMP 2023, Dr. Pradeep Nair discusses his presentation on the clinical data available on the Ranger drug-coated balloon.

In this video recorded at AMP...

11/13/2023

Vascular Disease Management

AMP 2023

The Value of Debulking and Vessel Prep Before Drug Delivery

11/09/2023

Craig Walker, MD, FACC, FACP

Cardiovascular Institute of the South, Houma, Louisiana

Craig Walker, MD, FACC, FACP Cardiov...

Dr. Craig Walker, from the Cardiovascular Institute of the South in Houma, Louisiana, discusses his presentation on using vessel prep before drug-coated balloon delivery.

Dr. Craig Walker, from the...

11/09/2023

Vascular Disease Management

Commentary

The Paclitaxel-Coated Conundrum: A Commentary Article

01/14/2020

Michael Patel, MD^1; Robert Beasley, MD, FSIR, FSCAI²

¹Department of Interventional Radiology, Mount Sinai Medical Center, Miami Beach, Florida; ²Robert Beasley, Section Chief, Vascular/ Interventional Radiology, Mount Sinai Medical Center, Miami Beach, Florida

Michael Patel, MD1; Robert Beasley, M...

Michael Patel, MD, and Robert Beasley, MD discuss drug-eluting stents and drug-coated balloons.

Michael Patel, MD, and Robert...

01/14/2020

Vascular Disease Management

FDA Panel

The Future is Going to Be Drug-Coated or Drug-Eluting. We Need Individual Patient Data to Move Forward.

06/27/2019

Konstantinos Katsanos, MSc, MD, PhD, EBIR

Assistant Professor, Interventional Radiology, School of Medicine, Patras University Hospital, Patras, Greece

Konstantinos Katsanos, MSc, MD, PhD, ...

VDM talks with Konstantinos Katsanos, MSc, MD, PhD, EBIR, Assistant Professor, Interventional Radiology, School of Medicine, Patras University Hospital, Patras, Greece.

VDM talks with Konstantinos...

06/27/2019

Vascular Disease Management

FDA Panel

A View on Drug-Coated Balloons From the Land of the Practicing Physician

06/21/2019

Jihad A. Mustapha, MD, FACC, FSCAI

Advanced Cardiac & Vascular Centers for Amputation Prevention, Grand Rapids, Michigan

Jihad A. Mustapha, MD, FACC, FSCAI ...

Jihad A. Mustapha, MD, comments on the use of drug-coated balloons.

Jihad A. Mustapha, MD, comments...

06/21/2019

Vascular Disease Management

Original Contribution

Outcomes With Drug-Coated Balloons for Treating the Side Branch of Coronary Bifurcation Lesions

09/15/2018

Michael Megaly, MD, MS^1,2; Michael Rofael, MD³; Marwan Saad, MD, MS^4,5; Mehdi Shishehbor, DO, MPH, PhD⁶; Emmanouil S. Brilakis, MD, PhD¹

Michael Megaly, MD, MS1,2; Michael R...

We performed a systematic review of all studies published between January 2000 and February 2018 reporting the outcomes of DCB vs non-coated balloon angioplasty (BA) in the treatment of the SB in coronary bifurcation lesions. Outcomes...

We performed a systematic review...

09/15/2018

Journal of Invasive Cardiology

Review

Should We Routinely Stent the Femoropopliteal Artery? An Interventionalist`s Perspective

11/01/2015

Nicolas W. Shammas, MD, MS¹ and Subhash Banerjee, MD²

Nicolas W. Shammas, MD, MS1 and Subha...

An overview of the pros and cons of primary stenting of femoropopliteal (FP) arteries vs alternative approaches including provisional stenting following POBA, atherectomy and/or drug-coated balloons.

An overview of the pros and cons...

11/01/2015

Journal of Invasive Cardiology

Review

Drug-Eluting Stents and Drug-Coated Balloons in Peripheral Interventions

11/06/2008

Thomas Zeller, MD

Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

Thomas Zeller, MD Herz-Zentrum Bad K...

In the coronaries, the role of drug-eluting stents (DES) is already well defined. However, in the peripheral arteries very limited data exists about their potential benefit.

In the coronaries, the role of...

11/06/2008

Vascular Disease Management